Summary
Novo Nordisk provided updates on its next-generation obesity and diabetes drug, CagriSema, a potential successor to Ozempic and Wegovy.
CagriSema combines semaglutide with an amylin and calcitonin receptor agonist, promising enhanced weight loss and blood sugar regulation.
Early trials showed 15.6% weight loss over 32 weeks, and executives are optimistic larger trials could show up to 25% weight loss.
Results from late-stage trials are expected by mid-2025.
And so, the cycle of minor, but copyrighted updates begins.
deleted by creator
It’s a happy accident. They were working on a diabetes treatment, which they did develop. The side effects included weight loss, so it started to get prescribed off-label for that. Then they did the required testing to get it approval for weight-loss.
It works because it is a fake hormone that mimics GLP-1, a hormone that is involved with appetite regulation. When it binds to the GLP-1 receptors it causes more insulin to be released in response to sugars which lowers blood sugars. The weight loss doesn’t come from that, though, it comes from the appetite suppression.
A lot of people seem to think you can eat as much as you want while you’re taking it. That’s technically true, but really because you won’t want to eat much.
Ohh yes daddy, give me that good shit
